Pelthos Therapeutics Inc. (PTHS)
Pelthos Therapeutics Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Pelthos Therapeutics Inc. (PTHS) is a Biotechnology company based in US with a market capitalization of $17.4M. Free cash flow was negative at -$22.7M. This page tracks PTHS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 4 employees · IPO Jul 2, 2025
Valuation
Valuation & price
$26.72as of May 17, 2026· -28.6% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.45
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$17.4M
Market cap
—
Revenue growth (YoY)
62.6%
Gross margin
-$22.7M
Free cash flow (USD)
$16.8M
Net debt
220.0%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2020 → 2025
Free cash flow by year
2022 → 2025
Value screen
Graham defensive-investor tests
1
Insider buys · 90 days
5
Insider sells · 90 days
Earnings
Last reported: May 14, 2026 (EPS $-3.09)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider sellJul 7, 2026Filing
Insider Sell $21K · 10b5-1 PlanGreenleaf Peter · Director · $20.8K
- Insider sellJul 7, 2026Filing
Insider Sell $21K · 10b5-1 PlanPauls Matthew · Director · $20.6K
- Insider sellJul 7, 2026Filing
Insider Sell $15K · 10b5-1 PlanFriedberg Ezra M · Director · $14.6K
- Insider sellJun 17, 2026Filing
Insider Sell $8K · 10b5-1 PlanFriedberg Ezra M · Director · $7.7K
- Insider buyJun 15, 2026Filing
Insider Buy $1000KDavis Todd C · Director · $1M
- 8-K eventMay 28, 2026Filing
Investor Conference Participation
- Insider sellMay 26, 2026Filing
Insider Sell $40KFrancis Knuettel II · CFO, Treas & Secty · $40.3K
- 8-K eventMay 21, 2026Filing
Employee Termination
- Quarterly reportMay 14, 2026Filing
10-Q Filed
- 8-K eventMay 14, 2026Filing
Earnings Release
Questions
Frequently asked questions
What is Pelthos Therapeutics Inc.'s market cap?
Pelthos Therapeutics Inc. (PTHS) has a market capitalization of $17.4M.
What is PTHS's P/E ratio?
A meaningful P/E ratio is not available for PTHS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is PTHS's price-to-book (P/B) ratio?
PTHS trades at 0.45 times book value per share.
When did Pelthos Therapeutics Inc. last report earnings?
PTHS last reported earnings on May 14, 2026; the next date is not yet scheduled.
Are insiders buying PTHS stock?
Yes — SEC Form 4 filings show 1 open-market insider buy and 5 sells at Pelthos Therapeutics Inc. in the last 90 days.
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.